Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Current Deferred Revenue (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Current Deferred Revenue for 6 consecutive years, with $28.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue rose 11.82% year-over-year to $28.5 million, compared with a TTM value of $28.5 million through Dec 2025, up 11.82%, and an annual FY2025 reading of $28.5 million, up 11.82% over the prior year.
  • Current Deferred Revenue was $28.5 million for Q4 2025 at Cytek Biosciences, down from $28.7 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $28.7 million in Q3 2025 and bottomed at $4.7 million in Q2 2021.
  • Average Current Deferred Revenue over 5 years is $19.0 million, with a median of $22.9 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue crashed 46.23% in 2021, then soared 241.0% in 2022.
  • Year by year, Current Deferred Revenue stood at $7.1 million in 2021, then surged by 83.39% to $13.0 million in 2022, then surged by 74.77% to $22.7 million in 2023, then grew by 12.32% to $25.5 million in 2024, then increased by 11.82% to $28.5 million in 2025.
  • Business Quant data shows Current Deferred Revenue for CTKB at $28.5 million in Q4 2025, $28.7 million in Q3 2025, and $28.1 million in Q2 2025.